# Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study

Study · id `cardio:ct-nct03244241` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03244241](<https://clinicaltrials.gov/study/NCT03244241>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03244241

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT03244241. Randomized; no masking; primary purpose treatment. Start 2017-04-01 (actual); primary completion 2018-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT03244241, source copy `cardio:ctgov-nct03244241-2017-08-09`, retrieved 2026-10-26)
- Started: 2017-04-01 (actual) (ClinicalTrials.gov record NCT03244241, source copy `cardio:ctgov-nct03244241-2017-08-09`, retrieved 2026-10-26)
- Primary completion: 2018-04-01 (anticipated) (ClinicalTrials.gov record NCT03244241, source copy `cardio:ctgov-nct03244241-2017-08-09`, retrieved 2026-10-26)
- Completion: 2018-04-01 (anticipated) (ClinicalTrials.gov record NCT03244241, source copy `cardio:ctgov-nct03244241-2017-08-09`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT03244241, source copy `cardio:ctgov-nct03244241-2017-08-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03244241-2017-08-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin Degludec 100 UNT/ML \[Tresiba\]
- Lead sponsor: Merete Bechmann Christensen
- Lead sponsor class: OTHER
- Collaborator: Novo Nordisk A/S
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 01b215b209e2fd34db837cb64931c0ccca93457f07d6978fe9ebfb00fdfe3800
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
